9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $80M | -$39M | 67.7% | -42.0% | -$29M | $56M | $51M |
| 2024 | $69M | -$38M | 67.1% | -49.2% | -$43M | $41M | $53M |
| 2023 | $58M | -$47M | 68.6% | -75.4% | -$41M | $41M | $47M |
| 2022 | $41M | -$44M | 65.3% | -94.2% | -$42M | $40M | $42M |
| 2021 | $29M | -$33M | 63.9% | -100.0% | -$31M | $31M | $44M |
| 2020 | $18M | -$29M | 61.7% | -138.8% | -$25M | $31M | $74M |
| 2019 | $15M | -$22M | 60.0% | -124.1% | -$26M | $30M | $45M |
| 2018 | $8M | -$21M | 35.6% | -214.9% | -$20M | — | $17M |
| 2017 | $4M | -$21M | 59.6% | -398.7% | -$16M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $19M | -$12M | 65.7% | -55.2% | -$11M | $56M | $40M |
| Dec '25 | $21M | -$9M | 65.9% | -31.9% | -$5M | $56M | $51M |
| Sep '25 | $21M | -$9M | 67.5% | -36.5% | -$6M | $41M | $30M |
| Jun '25 | $20M | -$10M | 69.8% | -45.0% | -$8M | $41M | $35M |
| Mar '25 | $19M | -$11M | 67.6% | -56.5% | -$10M | $41M | $43M |
| Dec '24 | $18M | -$9M | 63.6% | -47.3% | -$8M | $41M | $53M |
| Sep '24 | $19M | -$10M | 67.8% | -49.4% | -$9M | $41M | $17M |
| Jun '24 | $16M | -$13M | 68.8% | -71.9% | -$11M | $41M | $26M |
| Mar '24 | $17M | -$6M | 68.3% | -29.1% | -$15M | $41M | $37M |
| Dec '23 | $17M | -$13M | 68.4% | -72.2% | -$11M | $41M | $47M |
| Sep '23 | $15M | -$11M | 69.0% | -67.6% | -$7M | $40M | $58M |
| Jun '23 | $14M | -$11M | 70.4% | -71.5% | -$11M | $40M | $65M |
| Mar '23 | $12M | -$12M | 66.3% | -94.5% | -$12M | $40M | $30M |
| Dec '22 | $12M | -$10M | 70.3% | -81.2% | -$11M | $40M | $42M |
| Sep '22 | $11M | -$11M | 65.6% | -85.0% | -$8M | $40M | $54M |
| Jun '22 | $10M | -$13M | 62.9% | -98.4% | -$12M | $40M | $28M |
| Mar '22 | $8M | -$11M | 60.7% | -119.6% | -$11M | $32M | $33M |
| Dec '21 | $8M | -$9M | 67.6% | -91.4% | -$10M | $31M | $44M |
| Sep '21 | $8M | -$8M | 60.1% | -94.3% | -$7M | $31M | $54M |
| Jun '21 | $8M | -$8M | 67.3% | -96.7% | -$6M | $31M | $60M |
How the market has priced TELA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, TELA Bio, Inc.'s revenue has grown 34.5% per year. These are computed facts, not advice.
As of FY2025, TELA Bio, Inc. reported $56M of total debt against $51M of cash; operating income covered interest expense -6.4×.
In FY2025, gross margin was 67.7%, operating margin -42.0%, and net margin -48.3%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.